Topamax (Topiramate) is an anticonvulsant medication that is primarily used for the treatment of epilepsy, but has also been approved for migraine prevention and as an adjunct to phentermine for weight loss. It is also commonly used as an off-label medication to treat bipolar disorder as well as borderline personality disorder, but there is no …
Vyvanse (Lisdexamfetamine) is a psychostimulant medication that was developed by the company Shire. It is primarily prescribed for the treatment of ADHD (attention deficit hyperactivity disorder) and works well to improve cognitive function. In addition to treating ADHD, many doctors have used the drug to help individuals with excessive daytime sleepiness and binge eating disorders. …
Adderall is arguably the single most popular psychostimulant medication on the market. In addition to being a highly effective treatment option for ADHD (attention-deficit hyperactivity disorder), it is also sometimes used to treat narcolepsy, and as an antidepressant augmentation strategy. Many doctors don’t mind prescribing this drug to patients with non-addictive personalities because it has been …
Geodon (Ziprasidone) is an atypical antipsychotic that was approved by the FDA in 2001 for the treatment of schizophrenia. It has since been approved to manage both manic and mixed states of bipolar disorder. In some cases, the drug is used as an antidepressant augmentation strategy for the treatment of refractory depression, as well as …
Latuda (Lurasidone) is a relatively new atypical antipsychotic that was approved in 2013 for the treatment of schizophrenia and depressive episodes in Type 1 Bipolar disorder. Many have made the argument that since this is a “newer” antipsychotic, it’s likely to be “better” than the crop of older medications on the market. While no single …
Wellbutrin (Bupropion) is considered an atypical antidepressant and smoking cessation aid that was first approved for medical use in 1989. It functions different than most antidepressants in that it inhibits the reuptake of stimulatory neurotransmitters norepinephrine and (to a lesser degree) dopamine. Its action as an NDRI drug generally results in increased energy, focus, and …
Viibryd (Vilazodone) is a drug that was developed by Merck for the treatment of clinical depression. It was approved in the United States as an antidepressant medication in 2011. It functions as an atypical serotonergic antidepressant. Although some consider it to be similar to SSRIs, it differs in that it is unlikely to cause significant …